An FDA panel delayed review of an AIDS drug.

The FDA’s outside expert panel needs more time to study data on Syntex Corp.’s drug Cytovene, according to the FDA and Syntex. The drug is intended as a treatment for an infection called cytomegalovirus, a common cause of death in AIDS patients. The views of the FDA’s outside expert panels traditionally carry great weight with agency officials when the time comes to decide whether to approve experimental drugs for marketing.